fda on semaglutide New Weight Loss Medication Wegovy™ Approved by the FDA Approves Oral Semaglutide as

You may have heard discussions around the use of GLP-1s to treat obesity, which has raised questions about whether health insurers should cover these medications for weight loss

Your provider will recommend the right option for your health profile

Was sagen Sie dazu

When troche or liquid is used, the medication is absorbed in the mouth and lower doses can be used

Expert perspective Yoonhyuk Jang, MD, PhD, Postdoctoral Fellow in the Department of Immunology at Harvard Medical School, commented on the findings: This study suggests that semaglutide may be associated with a lower risk of adult-onset seizures or epilepsy in patients with type 2 diabetes, with the signal appearing more pronounced in late-onset cases among adults aged 60 years or older. He added: Given that age-associated brain insults are major contributors to adult-onset seizures and epilepsy, these findings may have implications beyond seizure risk alone and raise the possibility that semaglutide could also be relevant to broader brain health